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ScienceDirectSchizophrenia is a common psychiatric disorder with a strong
genetic component. Recent studies applying new genomic
technology to large samples have yielded substantial advances
in identifying specific, associated DNA variants as well as
clarifying the underlying genetic architecture of the disorder.
The genetic liability of schizophrenia is now established as
polygenic, with risk alleles in many genes existing across the
full allelic frequency spectrum. It has also become apparent
that schizophrenia shares risk alleles with other
neuropsychiatric phenotypes, such as bipolar disorder, major
depressive disorder, autism spectrum disorder, intellectual
disability and attention-deficit hyperactivity disorder. These risk
variants aggregate in several sets of functionally related genes,
thereby providing novel insights into disease pathogenesis and
opportunities for research into discovering new treatments.
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Introduction
Schizophrenia is a debilitating psychiatric disorder,
characterised by hallucinations, delusions, thought dis-
order and cognitive deficits, and has a lifetime prevalence
of around 1%. Evidence for a substantial genetic contri-
bution comes from family, twin and adoption studies [1]
but the underlying causes and pathogenesis of the dis-
order remains unknown. The past few years have wit-
nessed marked progress in our understanding of genetic
risk at the level of DNA variation, which has been largely
driven by applying advanced genomic technologies to
very large samples. There is evidence that risk variants
occur across the full allelic frequency spectrum, many of
which are associated with other neuropsychiatric dis-
orders. Moreover, genetic associations involving differentCurrent Opinion in Behavioral Sciences 2015, 2:8–14 classes of mutations have now implicated specific bio-
logical pathways in disease pathogenesis. This review will
cover recent advances in schizophrenia genetics from
studies of de novo mutation, rare copy number variation
(CNV), rare single nucleotide variant (SNV, defined as
point mutations with a frequency less than 1%) and small
insertion/deletion (indel) mutations and single nucleotide
polymorphisms (SNPs, defined as point mutations with a
frequency greater than 1%) (Figure 1).
De novo mutations
High heritability estimates for schizophrenia suggest that
much of the risk is inherited [2]. However, alleles which
are not inherited, i.e. newly arising (de novo) mutations,
have also been shown to contribute to risk. In addition,
increased paternal age at conception, which is correlated
with the number of de novo mutations observed in an
individual [3,4], has been associated with increased
schizophrenia risk [5]. The first molecular evidence
associating de novo mutation with schizophrenia came
from studies of CNVs [6–8]. Across studies, the CNV
de novo mutation rate was found to be significantly elev-
ated in schizophrenia (5%) versus controls (2%), with
some evidence for a higher rate among patients with no
family history of the disorder [6–8]. The median size of de
novo CNVs > 100 Kb found in schizophrenia cases
(574 Kb [6–8]) is also larger compared with that in controls
(337 Kb [6–9]). Selection coefficients (s) between 0.12 and
0.88 have been estimated for CNVs robustly associated
with schizophrenia (a selection coefficient of 1 being
reproductively lethal) [10]. With this intensity of selection,
de novo CNVs at schizophrenia-associated loci are purged
from the population in less than five generations [10].
Studying gene-sets overrepresented for being disrupted
by de novo mutation in schizophrenia has provided novel
insights into biological pathways underlying the disorder.
For example, genes disrupted by schizophrenia de novo
CNVs are enriched for those in the post-synaptic-density
proteome [6]. This association is largely driven by genes
encoding members of the N-methyl-D-aspartate receptor
(NMDAR) and neuronal activity-regulated cytoskeleton-
associated protein (ARC) complexes, both of which are
involved in synaptic plasticity [6].
More recently, exome sequencing studies have permitted
the evaluation of de novo SNV mutations and indels in
schizophrenia. In contrast to studies of de novo CNVs in
schizophrenia, the exome-wide rate of de novo SNV/indel
mutations is not increased in cases compared with the
population expectation [11]. Some smaller studies have
reported slightly elevated rates of de novo SNV mutations,www.sciencedirect.com
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Schizophrenia risk alleles. Bullet points summarise some of the key findings covered in this review. MAF = minor allele frequency, OR = odds ratio,
CNV = copy number variation, SNV = single nucleotide variant, indel = insertion/deletion, ARC = activity-regulated cytoskeleton-associated protein,
NMDAR = N-methyl-D-aspartate receptor, FMRP = fragile X mental retardation protein, BD = bipolar disorder, MDD = major depressive disorder,
ASD = autism spectrum disorder.as well as a greater proportion of de novo mutations
occurring as nonsynonymous, in schizophrenia compared
with controls [12–14], but these findings were not
observed in the largest study till date [11]. However,
loss-of-function de novo SNV/indel mutations are
enriched among patients with poor educational attain-
ment (these cases did not have intellectual disability)
[11]. Multiple schizophrenia loss-of-function de novo
SNV/indel mutations have been observed in two genes
(TAF13, SETD1A) [11,15], suggesting they are likely to
be relevant to the disorder.
The products of genes disrupted by damaging de novo
mutations in schizophrenia show greater connectivity in
protein–protein interaction (PPI) networks than expected
by chance [13] or compared with controls [14]. Genes
disrupted by nonsense de novo mutations in schizophrenia
have also been shown to preferentially occur in genes
subject to haploinsufficiency [12], suggesting many
are likely to be pathogenic. Despite the lack of an
increased exome-wide rate of de novo SNV/indel mutationwww.sciencedirect.com in schizophrenia, these mutations are enriched among
cases in previously associated sets of biologically related
genes. Specifically, the ARC and NMDAR postsynaptic
protein complexes, associated with schizophrenia in stu-
dies of de novo CNVs, have been further implicated through
significant enrichments in cases for nonsynonymous and
loss-of-function de novo mutations [11]. Brain expressed
genes targeted by fragile X mental retardation protein
(FMRP) also show evidence for significant enrichments
of de novo SNV/indel mutations in schizophrenia [11]
following an earlier observation for a similar enrichment for
de novo mutations in ASD [16]. Other sets reported to be
enriched for de novo mutations include those related to the
assembly of actin filament bundles [11], genes related to
epigenetic regulation, specifically chromatin-remodelling
[12,13,15], and genes disrupted by de novo mutations in
ASD and intellectual disability (ID) [11].
Rare copy number variations
Studies of rare (<1%) CNVs in schizophrenia have now
reported several reproducible associations. It is establishedCurrent Opinion in Behavioral Sciences 2015, 2:8–14
10 Behavioral genetics 2015that patients with schizophrenia have a significantly
increased genome-wide burden of rare CNVs compared
with controls, with the strongest effect usually seen for
large (>500 Kb) deletions [17–20]. Since the discovery of a
deletion at 22q11.2 as the first schizophrenia-associated
CNV [21,22], analyses of rare CNVs involving >20,000
cases have revealed associations at more than 15 loci
[20,23,24] (Figure 2). The majority of these CNVs sub-
stantially increase the risk of developing schizophrenia,
with odds ratios (OR) between two and 60 [24]. As their
frequency among patients is often less than one in 500,
their individual contribution to the total population vari-
ation in schizophrenia genetic liability is small [25],
although collectively they are found in around 2.5% of
patients [24]. Most schizophrenia-associated CNVs are
large and recurrent, meaning multiple mutation events
have occurred at the exact same, or near identical, genomic
location. The breakpoints of recurrent CNVs are usually
flanked by repetitive genomic elements such as low copyFigure 2
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Current Opinion in Behavioral Sciences 2015, 2:8–14 repeats (LCRs), which mediate mutation through non-
allelic homologous recombination [26]. 10 recurrent CNVs
have been associated with schizophrenia at a level of
statistical support that survives correction for the multiple
testing of 120 potential recurrent CNV loci in the human
genome (Figure 2). Drawing biological insights from recur-
rent CNVs remains a challenge, largely because multiple
genes and regulatory elements are often disrupted. How-
ever, single-gene disrupting non-recurrent CNVs have also
been associated with schizophrenia at NRXN1, VIPR2 and
PAK7. These mutations have the potential to offer clearer
insights into disease pathogenesis, although only the
NRXN1 association survives correction for the multiple
testing of all human genes (20,000). NRXN1 encodes a
synaptic cell adhesion molecule neurexin 1 that links
presynaptic and postsynaptic neurons [27].
Gene-set analyses have shown rare CNVs in schizophrenia
to be enriched among biological pathways previouslyControls
Schizophrenia
4.94
OR = 2.72
9
OR = NA
OR = 2.30
OR = 11.52
OR = 2.15
= 13.20
OR = 7.52
11.35
= 57.65
OR = 3.45
OR = 8.35
OR = 9.01
OR = 3.99
 1.54
P = 4.4 x 10–40
P = 5.7 x 10–5
P = 2.9 x 10–24
10
P = 2.5 x 10–10
 10–11
x 10–4
0–13
= 3.62
0.3
quency (%)
0.4 0.5 0.6
Current Opinion in Behavioral Sciences 
 with a 2-sided Fisher’s Exact test. P values which survive correction for
5  106) are highlighted in bold. Del = deletions, dup = duplications,
S = Williams-Beuren syndrome. CNV frequencies in schizophrenia cases
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metabotropic glutamate receptor 5 (mGluR5) components
of the post synaptic density (PSD), calcium channel signal-
ling (see single nucleotide polymorphisms below) and
FMRP targets [20]. Additional gene-sets recently impli-
cated in rare CNV studies include signalling components
within the immune system, chromatin remodelling com-
plexes and targets of microRNA miR-10a [20].
Schizophrenia-associated CNVs have been shown to
increase risk for additional neuropsychiatric disorders
[28,29]. For example, schizophrenia-associated dupli-
cations of the Williams-Beuren and Prader-Willi/Angel-
man syndrome regions are also implicated in ASD [9,30],
deletions of 15q11.2 and 15q13.3 in epilepsy [31,32] and
duplications of 16p13.11 in attention-deficit hyperactivity
disorder (ADHD) [33]. Up to 72 pathogenic CNVs, which
include the majority of those presented in Figure 2, are
enriched in large cohorts of patients with early onset
neurodevelopmental phenotypes, such as ID, ASD and
congenital malformations (CM) [34,35]. It has been
suggested that individuals carrying more than one patho-
genic CNV are at greater risk of developing an earlier
onset neurodevelopmental disorder (ID/ASD/CM) com-
pared with schizophrenia [36]. In some instances, reci-
procal CNVs (i.e. deletion and duplications at the same
locus) appear to have different phenotypic effects. For
example, deletions and duplications at 16p11.2 are associ-
ated with obesity and low body mass index, respectively
[37]. In schizophrenia, duplications at 22q11.2 are signifi-
cantly less common than they are in controls, whereas the
deletion of this locus is one of its strongest risk factors
[38].
The CNVs in Figure 2 are considered to have fairly high,
but incomplete, penetrance for schizophrenia and for
other neurodevelopmental disorders, most having lower
penetrance for schizophrenia than the other disorders
[28]. However, the incomplete penetrance of these
CNVs has recently been questioned in a large study
which showed the level of cognitive performance in
non-affected carriers of schizophrenia-associated CNVs
to be in-between that observed in schizophrenia patients
and population controls [39].
Rare single nucleotide variant and insertion/
deletion mutations
Over the past few years, several publications have used
new sequencing technology to investigate rare inherited
(as opposed to de novo) alleles in schizophrenia. Intriguing
findings have been reported from some studies [40,41],
although their results largely remain inconclusive owing
to small sample size. Only one schizophrenia study till
date has employed exome sequencing in large samples
(2536 cases and 2543 controls) [42]. No single rare allele
(MAF < 0.1%) was associated at genome-wide levels of
significance, and overall, the exome-wide burden of rarewww.sciencedirect.com variation was not increased in cases. However, a signifi-
cantly increased burden of rare, disruptive alleles was
observed in a set of 2546 genes selected for a higher
probability of being associated with schizophrenia. This
burden was distributed across a large number of genes. As
in the de novo CNV and SNV studies, significant enrich-
ments for rare disruptive SNVs and indels were found in
proteins affiliated with ARC and NMDAR genes, and
FMRP-targets, but also for voltage-gated calcium chan-
nels [42]. This work demonstrates a contribution of
ultra-rare damaging alleles spread across a large number
of genes in schizophrenia, although larger samples are
required for robust associations to be made to specific
genes/alleles.
Single nucleotide polymorphisms
Genome-wide association studies (GWAS) of SNPs have
now identified a number of common schizophrenia risk
alleles [43–45]. Individually, these alleles have a weak
effect on schizophrenia risk, with ORs generally < 1.2,
although collectively they are estimated to account for
between a third and a half of the variation in schizophrenia
genetic liability [43,46,47]. Given the modest effect size
of these alleles, very large samples have been required
to obtain the necessary statistical power for associations
to be made at genome-wide levels of significance
(P < 5  108). Until recently, the number of individual
alleles identified at genome-wide levels of significance was
small (n < 30) [43], although en masse analysis of GWAS
data had established the disorder to have a polygenic
component likely to involve over a thousand common
alleles [43,46,48]. Recent successes in the identification
of schizophrenia common allele associations can largely be
attributed to the Schizophrenia Working Group of the
Psychiatric Genomics Consortium (PGC), which was cre-
ated with the aim to maximise sample size by combining
GWAS data from multiple international research groups
[49]. The latest data from the PGC identified 128 linkage
disequilibrium (LD)-independent genome-wide signifi-
cant associations in 108 distinct loci [45]. The most
significant allelic association in schizophrenia is in the
extended major histocompatibility complex (MHC) on
the short arm of chromosome 6 [45]. Identifying candi-
date genes from this association is a major challenge as the
existence of strong LD across this region of about 8Mb
makes it difficult to localise the association to one, or even a
few, of the hundreds of genes at the locus. The MHC’s
involvement in immunity suggests that immune dysfunc-
tion might play a role schizophrenia, although non-immune
genes are also found in this region [50]. Additional genome-
wide significant associations are found in genes long
believed to play a major role in schizophrenia, such as
the dopamine receptor D2 gene, which encodes the thera-
peutic target of most antipsychotic drugs [45]. This
suggests that biological insights gained from other novel
common allele associations have the potential to identify
new drug targets. Gene-set analyses have not yet shownCurrent Opinion in Behavioral Sciences 2015, 2:8–14
12 Behavioral genetics 2015any biological pathway to be significantly enriched for the
128 schizophrenia genome-wide significant associations
after correction for multiple testing, and a definitive
analysis is awaited [45]. However, the associations are
enriched for enhancers expressed in brain, and also for
enhancers in tissues involved with immunity [45].
Schizophrenia has been shown to share common risk
alleles with other psychiatric disorders, such as bipolar
disorder (BP), major depressive disorder (MDD), ASD
and ADHD [51]. The most powerful demonstration of
this comes from the en masse effects of SNPs which have
revealed a high genetic overlap between schizophrenia
and BP, a moderate overlap between schizophrenia and
MDD, and a small but significant overlap between schizo-
phrenia and ASD [46,48]. Combining GWAS data from
schizophrenia and BD has proved fruitful in identifying
common risk alleles [52,53], although polygenic risk
scores have also been able partly to distinguish between
these disorders, suggesting that some risk alleles may
confer more specific effects at the level of the psychiatric
phenotype [53]. Schizophrenia polygenic risk scores have
also been shown to predict lower cognitive ability [54],
suggesting these alleles contribute to the cognitive def-
icits associated with the disorder.
Conclusion
It is now established that the genetic architecture of
schizophrenia involves rare, common and de novo risk
alleles distributed across a large number of genes. Despite
substantial genetic heterogeneity, different classes of
mutation have been shown to converge onto common
biological pathways, implicating neuronal calcium signal-
ling, components of the post synaptic density, synaptic
plasticity, epigenetic regulation and the immune system
in the disorder. It has also become clear that schizo-
phrenia shares risk alleles with other neuropsychiatric
disorders, with evidence of a gradient of mutational
severity with intellectual disability and schizophrenia
at the most extreme and moderate ends of this spectrum,
respectively [55]. It is inevitable that further increases in
sample size in both GWAS and sequencing studies will
identify additional risk alleles and whole-genome se-
quencing will allow for more complex types of genetic
variation to be examined, while permitting the investi-
gation of rare alleles in regulatory elements.
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